Bolt Biotherapeutics Key Executives
This section highlights Bolt Biotherapeutics's key executives, including their titles and compensation details.
Find Contacts at Bolt Biotherapeutics
(Showing 0 of )
Bolt Biotherapeutics Earnings
This section highlights Bolt Biotherapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2024 | 2024-05-17 | N/A | N/A |
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
$0.39
Stock Price
$14.95M
Market Cap
52
Employees
Redwood City, CA
Location
Financial Statements
Access annual & quarterly financial statements for Bolt Biotherapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $7.69M | $7.88M | $5.73M | $1.26M | $231.00K |
| Cost of Revenue | $- | $1.88M | $4.89M | $3.67M | $40.36M |
| Gross Profit | $7.69M | $5.99M | $838.00K | $-2.41M | $-40.13M |
| Gross Profit Ratio | 100.00% | 76.08% | 14.63% | -191.43% | -17370.56% |
| Research and Development Expenses | $57.47M | $61.54M | $73.12M | $75.66M | $40.36M |
| General and Administrative Expenses | $18.46M | $22.53M | $22.93M | $18.39M | $9.06M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $18.46M | $22.53M | $22.93M | $18.39M | $9.06M |
| Other Expenses | $4.81M | $- | $- | $-6.08M | $-11.74M |
| Operating Expenses | $80.74M | $84.07M | $96.05M | $94.05M | $49.41M |
| Cost and Expenses | $80.74M | $84.07M | $96.05M | $94.05M | $49.41M |
| Interest Income | $5.25M | $7.00M | $2.22M | $281.00K | $199.00K |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $1.78M | $1.85M | $4.89M | $3.67M | $2.50M |
| EBITDA | $-66.45M | $-74.34M | $-88.66M | $-91.59M | $-48.57M |
| EBITDA Ratio | -864.17% | -943.91% | -1547.48% | -7269.44% | -21026.41% |
| Operating Income | $-73.05M | $-76.20M | $-90.32M | $-92.79M | $-49.18M |
| Operating Income Ratio | -949.91% | -967.45% | -1576.56% | -7364.13% | -21290.91% |
| Total Other Income Expenses Net | $9.93M | $7.00M | $2.22M | $-5.80M | $-11.55M |
| Income Before Tax | $-63.12M | $-69.20M | $-88.10M | $-98.59M | $-60.73M |
| Income Before Tax Ratio | -820.78% | -878.58% | -1537.76% | -7824.68% | -26289.18% |
| Income Tax Expense | $- | $- | $-2.22M | $5.80M | $11.55M |
| Net Income | $-63.12M | $-69.20M | $-85.88M | $-104.39M | $-72.27M |
| Net Income Ratio | -820.78% | -878.58% | -1498.95% | -8285.24% | -31287.45% |
| EPS | $-1.65 | $-1.83 | $-2.30 | $-2.79 | $-1.99 |
| EPS Diluted | $-1.65 | $-1.83 | $-2.30 | $-2.79 | $-1.99 |
| Weighted Average Shares Outstanding | 38.18M | 37.81M | 37.36M | 37.40M | 36.25M |
| Weighted Average Shares Outstanding Diluted | 38.18M | 37.81M | 37.36M | 37.40M | 36.25M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $1.14M | $1.27M | $5.27M | $2.09M | $2.53M | $1.43M | $1.83M | $1.41M | $2.11M | $1.39M | $813.00K | $508.00K | $752.00K | $- | $- | $- | $- | $67.00K | $164.00K |
| Cost of Revenue | $- | $- | $15.43M | $458.00K | $497.00K | $462.00K | $1.19M | $1.19M | $1.17M | $18.97M | $18.92M | $1.53M | $905.00K | $19.34M | $900.00K | $802.00K | $14.86M | $9.54M | $9.17M | $6.79M |
| Gross Profit | $- | $1.14M | $-14.16M | $4.82M | $1.59M | $2.07M | $244.00K | $640.00K | $244.00K | $-16.86M | $-17.53M | $-715.00K | $-397.00K | $-18.59M | $-900.00K | $-802.00K | $-14.86M | $-9.54M | $-9.10M | $-6.62M |
| Gross Profit Ratio | 0.00% | 100.00% | -1110.43% | 91.32% | 76.21% | 81.72% | 17.03% | 35.05% | 17.29% | -798.34% | -1258.22% | -87.95% | -78.15% | -2471.41% | - | - | - | - | -13580.60% | -4038.41% |
| Research and Development Expenses | $11.72M | $13.79M | $15.43M | $16.07M | $15.82M | $14.95M | $15.64M | $14.62M | $16.84M | $18.97M | $18.92M | $18.39M | $22.48M | $19.34M | $19.71M | $14.13M | $14.86M | $9.54M | $9.17M | $6.79M |
| General and Administrative Expenses | $3.95M | $3.80M | $4.87M | $5.84M | $5.53M | $5.76M | $5.62M | $5.62M | $5.61M | $5.49M | $5.53M | $6.30M | $5.10M | $4.94M | $4.05M | $4.30M | $2.06M | $2.87M | $2.01M | $2.12M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.95M | $3.80M | $4.87M | $5.84M | $5.53M | $5.76M | $5.62M | $5.62M | $5.61M | $5.49M | $5.53M | $6.30M | $5.10M | $4.94M | $4.05M | $4.30M | $2.06M | $2.87M | $2.01M | $2.12M |
| Other Expenses | $1.25M | $- | $3.56M | $4.67M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-6.08M | $-14.12M | $2.38M | $- | $- |
| Operating Expenses | $16.92M | $17.58M | $19.85M | $21.91M | $21.36M | $20.71M | $21.27M | $20.24M | $22.45M | $24.46M | $24.45M | $24.69M | $27.58M | $24.28M | $23.76M | $18.43M | $16.92M | $12.40M | $11.18M | $8.91M |
| Cost and Expenses | $16.92M | $17.58M | $23.87M | $22.37M | $21.86M | $20.71M | $21.27M | $20.24M | $22.45M | $24.46M | $24.45M | $24.69M | $27.58M | $24.28M | $23.76M | $18.43M | $16.92M | $12.40M | $11.18M | $8.91M |
| Interest Income | $980.00K | $1.27M | $1.40M | $1.61M | $1.86M | $1.93M | $1.77M | $1.44M | $1.04M | $587.00K | $395.00K | $198.00K | $- | $131.00K | $176.00K | $56.00K | $12.00K | $24.00K | $51.00K | $112.00K |
| Interest Expense | $- | $- | $- | $- | $1.44M | $- | $- | $- | $- | $- | $395.00K | $198.00K | $82.00K | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $426.00K | $440.00K | $457.00K | $458.00K | $497.00K | $462.00K | $1.19M | $1.19M | $1.17M | $439.00K | $1.07M | $1.53M | $905.00K | $1.06M | $900.00K | $802.00K | $221.00K | $179.00K | $110.00K | $101.00K |
| EBITDA | $-15.24M | $-16.00M | $-18.57M | $-16.63M | $-19.30M | $-17.72M | $-19.37M | $-17.95M | $-20.58M | $-21.91M | $-22.65M | $-23.52M | $-26.71M | $-23.22M | $-23.50M | $-18.15M | $-16.70M | $-12.23M | $-11.00M | $-8.64M |
| EBITDA Ratio | - | -1402.54% | -1456.86% | -315.40% | -923.84% | -700.99% | -1351.99% | -982.91% | -1458.40% | -1037.26% | -1626.06% | -2892.87% | -5258.66% | -3088.03% | - | - | - | - | -16417.91% | -5270.73% |
| Operating Income | $-16.92M | $-16.44M | $-22.60M | $-17.09M | $-19.77M | $-18.18M | $-19.83M | $-18.41M | $-21.04M | $-22.35M | $-23.06M | $-23.88M | $-27.07M | $-23.53M | $-23.76M | $-18.43M | $-16.92M | $-12.40M | $-11.11M | $-8.74M |
| Operating Income Ratio | - | -1441.10% | -1772.31% | -324.08% | -946.19% | -719.26% | -1383.95% | -1008.49% | -1491.14% | -1058.05% | -1655.35% | -2936.78% | -5329.72% | -3128.46% | - | - | - | - | -16582.09% | -5332.32% |
| Total Other Income Expenses Net | $980.00K | $1.27M | $1.40M | $6.28M | $1.86M | $1.93M | $1.77M | $1.44M | $1.04M | $587.00K | $395.00K | $198.00K | $-82.00K | $131.00K | $176.00K | $-6.03M | $-14.11M | $2.40M | $51.00K | $112.00K |
| Income Before Tax | $-15.94M | $-15.18M | $-21.20M | $-10.81M | $-17.90M | $-16.26M | $-18.06M | $-16.98M | $-20.00M | $-21.76M | $-22.66M | $-23.68M | $-27.16M | $-23.39M | $-23.59M | $-24.45M | $-31.04M | $-10.00M | $-11.06M | $-8.63M |
| Income Before Tax Ratio | - | -1330.06% | -1662.35% | -204.99% | -857.01% | -643.08% | -1260.08% | -929.90% | -1417.22% | -1030.26% | -1626.99% | -2912.42% | -5345.87% | -3111.04% | - | - | - | - | -16505.97% | -5264.02% |
| Income Tax Expense | $- | $- | $- | $414.72K | $1.90M | $-462.00K | $335.92K | $-1.44M | $-1.04M | $- | $-395.00K | $-198.00K | $-361.00K | $-761.00K | $-644.00K | $6.03M | $13.89M | $-2.40M | $- | $- |
| Net Income | $-15.94M | $-15.18M | $-21.20M | $-10.81M | $-17.90M | $-16.26M | $-18.06M | $-15.54M | $-18.95M | $-21.76M | $-22.27M | $-23.48M | $-27.16M | $-23.39M | $-23.59M | $-24.45M | $-31.04M | $-10.00M | $-11.06M | $-8.63M |
| Net Income Ratio | - | -1330.06% | -1662.35% | -204.99% | -857.01% | -643.08% | -1260.08% | -851.31% | -1343.30% | -1030.26% | -1598.64% | -2888.07% | -5345.87% | -3111.04% | - | - | - | - | -16505.97% | -5264.02% |
| EPS | $-0.42 | $-0.40 | $-0.56 | $-0.28 | $-0.47 | $-0.43 | $-0.48 | $-0.41 | $-0.50 | $-0.58 | $-0.60 | $-0.63 | $-0.73 | $-0.63 | $-0.64 | $-1.14 | $-0.97 | $-0.71 | $-0.79 | $-0.62 |
| EPS Diluted | $-0.42 | $-0.40 | $-0.56 | $-0.28 | $-0.47 | $-0.43 | $-0.48 | $-0.41 | $-0.50 | $-0.58 | $-0.60 | $-0.63 | $-0.73 | $-0.63 | $-0.64 | $-1.14 | $-0.97 | $-0.71 | $-0.79 | $-0.62 |
| Weighted Average Shares Outstanding | 38.29M | 38.25M | 38.13M | 38.07M | 37.94M | 37.87M | 37.75M | 37.68M | 37.55M | 37.45M | 37.29M | 37.13M | 37.27M | 37.21M | 36.60M | 21.50M | 31.85M | 13.99M | 13.99M | 13.99M |
| Weighted Average Shares Outstanding Diluted | 38.29M | 38.25M | 38.13M | 38.07M | 37.94M | 37.87M | 37.75M | 37.68M | 37.55M | 37.45M | 37.29M | 37.13M | 37.27M | 37.21M | 36.60M | 21.50M | 31.85M | 13.99M | 13.99M | 13.99M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $7.21M | $10.81M | $9.24M | $27.38M | $5.54M |
| Short Term Investments | $40.12M | $91.38M | $159.64M | $158.84M | $17.30M |
| Cash and Short Term Investments | $47.32M | $102.19M | $168.89M | $186.22M | $22.84M |
| Net Receivables | $1.17M | $- | $- | $- | $- |
| Inventory | $- | $- | $-800.00K | $-200.00K | $-12.00K |
| Other Current Assets | $2.33M | $3.52M | $3.86M | $2.94M | $2.52M |
| Total Current Assets | $50.81M | $105.71M | $172.75M | $189.16M | $25.36M |
| Property Plant Equipment Net | $24.89M | $24.08M | $28.52M | $30.60M | $16.38M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $22.88M | $26.41M | $23.94M | $85.35M | $1.56M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.04M | $3.59M | $2.59M | $2.61M | $3.23M |
| Total Non-Current Assets | $48.82M | $54.08M | $55.06M | $118.56M | $21.18M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $99.63M | $159.78M | $227.81M | $307.72M | $46.54M |
| Account Payables | $1.51M | $2.99M | $3.59M | $3.57M | $1.60M |
| Short Term Debt | $2.25M | $2.78M | $4.78M | $5.00M | $3.00M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $3.02M | $2.20M | $1.99M | $2.87M | $1.50M |
| Other Current Liabilities | $9.08M | $12.49M | $12.75M | $9.88M | $5.16M |
| Total Current Liabilities | $15.86M | $20.46M | $23.12M | $21.33M | $11.26M |
| Long Term Debt | $22.96M | $17.44M | $20.22M | $21.85M | $9.38M |
| Deferred Revenue Non-Current | $- | $9.11M | $12.92M | $14.21M | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $3.62M | $43.00K | $42.00K | $210.00K | $130.85M |
| Total Non-Current Liabilities | $26.58M | $26.59M | $33.18M | $36.27M | $140.22M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $42.43M | $47.04M | $56.30M | $57.60M | $151.49M |
| Preferred Stock | $- | $- | $227.81M | $307.72M | $105.30M |
| Common Stock | $- | $1.00K | $- | $- | $- |
| Retained Earnings | $-427.40M | $-364.29M | $-295.09M | $-206.99M | $-108.40M |
| Accumulated Other Comprehensive Income Loss | $- | $37.00K | $-919.00K | $-321.00K | $- |
| Other Total Stockholders Equity | $484.60M | $476.99M | $467.51M | $457.43M | $3.45M |
| Total Stockholders Equity | $57.20M | $112.74M | $171.51M | $250.12M | $-104.95M |
| Total Equity | $57.20M | $112.74M | $171.51M | $250.12M | $-104.95M |
| Total Liabilities and Stockholders Equity | $99.63M | $159.78M | $227.81M | $307.72M | $46.54M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $99.63M | $159.78M | $227.81M | $307.72M | $46.54M |
| Total Investments | $63.00M | $117.79M | $183.59M | $244.18M | $17.30M |
| Total Debt | $25.21M | $20.22M | $22.61M | $24.36M | $10.88M |
| Net Debt | $18.00M | $9.41M | $13.37M | $-3.03M | $5.33M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $7.21M | $9.37M | $6.20M | $4.26M | $10.81M | $9.16M | $13.45M | $14.84M | $9.24M | $10.62M | $22.62M | $44.02M | $27.38M | $23.65M | $58.30M | $95.48M | $5.54M | $17.79M | $45.31M | $-34.83M |
| Short Term Investments | $40.12M | $44.43M | $67.50M | $87.09M | $91.38M | $110.56M | $112.42M | $111.54M | $159.64M | $160.51M | $153.72M | $146.88M | $158.84M | $189.24M | $186.69M | $171.19M | $17.30M | $19.95M | $8.04M | $69.65M |
| Cash and Short Term Investments | $47.32M | $53.80M | $73.70M | $91.35M | $102.19M | $119.72M | $125.87M | $126.38M | $168.89M | $171.13M | $176.34M | $190.90M | $186.22M | $212.89M | $244.99M | $266.67M | $22.84M | $37.75M | $53.35M | $34.83M |
| Net Receivables | $1.17M | $- | $- | $900.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $-2.80M | $-2.00M | $-500.00K | $-800.00K | $- | $- | $- | $-200.00K | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.33M | $3.35M | $2.93M | $3.71M | $5.56M | $5.74M | $4.80M | $5.23M | $3.86M | $6.79M | $9.45M | $10.07M | $2.94M | $13.89M | $6.33M | $9.08M | $2.52M | $1.92M | $1.28M | $- |
| Total Current Assets | $50.81M | $57.15M | $76.63M | $95.06M | $105.53M | $125.47M | $130.67M | $131.61M | $172.75M | $174.83M | $181.26M | $196.09M | $189.16M | $222.49M | $248.15M | $271.21M | $25.36M | $39.68M | $54.63M | $34.83M |
| Property Plant Equipment Net | $24.89M | $20.32M | $21.64M | $22.85M | $24.08M | $25.14M | $26.23M | $27.39M | $28.52M | $29.68M | $29.13M | $29.91M | $30.60M | $30.87M | $30.55M | $15.42M | $16.38M | $17.08M | $12.31M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $22.88M | $30.60M | $23.83M | $23.23M | $28.18M | $21.64M | $31.22M | $44.59M | $23.94M | $38.43M | $47.28M | $54.31M | $85.35M | $77.64M | $65.94M | $36.24M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.04M | $1.27M | $2.07M | $1.76M | $2.00M | $3.11M | $2.58M | $2.60M | $2.59M | $2.56M | $2.56M | $2.48M | $2.61M | $2.56M | $2.43M | $1.77M | $4.80M | $4.98M | $1.21M | $-34.83M |
| Total Non-Current Assets | $48.82M | $52.19M | $47.55M | $47.84M | $54.25M | $49.89M | $60.03M | $74.57M | $55.06M | $70.68M | $78.97M | $86.70M | $118.56M | $111.06M | $98.92M | $53.43M | $21.18M | $22.06M | $13.51M | $-34.83M |
| Other Assets | $- | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $99.63M | $109.33M | $124.18M | $142.89M | $159.78M | $175.35M | $190.70M | $206.18M | $227.81M | $245.50M | $260.24M | $282.79M | $307.72M | $333.55M | $347.07M | $324.64M | $46.54M | $61.74M | $68.14M | $- |
| Account Payables | $1.51M | $1.48M | $2.63M | $2.22M | $2.99M | $3.68M | $3.44M | $1.83M | $3.59M | $3.83M | $3.36M | $4.45M | $3.57M | $5.16M | $1.61M | $2.89M | $1.60M | $3.40M | $1.84M | $- |
| Short Term Debt | $2.25M | $2.73M | $5.99M | $2.89M | $5.56M | $5.36M | $5.16M | $4.97M | $2.39M | $4.77M | $4.29M | $4.12M | $2.50M | $4.82M | $4.65M | $3.26M | $1.50M | $1.35M | $1.43M | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $3.02M | $1.97M | $2.02M | $1.91M | $2.20M | $1.94M | $1.69M | $1.60M | $1.99M | $3.17M | $3.51M | $3.45M | $2.87M | $5.21M | $4.33M | $1.50M | $1.50M | $1.50M | $- | $- |
| Other Current Liabilities | $9.08M | $11.81M | $7.26M | $9.71M | $9.70M | $7.77M | $7.33M | $7.85M | $15.14M | $12.41M | $7.46M | $7.29M | $12.38M | $8.51M | $8.66M | $4.37M | $6.66M | $3.66M | $4.68M | $- |
| Total Current Liabilities | $15.86M | $18.08M | $17.90M | $16.72M | $20.46M | $18.75M | $17.62M | $16.25M | $23.12M | $24.17M | $18.62M | $19.31M | $21.33M | $23.70M | $19.25M | $12.01M | $11.26M | $9.90M | $7.95M | $- |
| Long Term Debt | $22.96M | $15.35M | $15.90M | $16.68M | $17.44M | $18.18M | $18.89M | $19.57M | $20.22M | $20.86M | $20.75M | $21.31M | $21.85M | $22.52M | $23.16M | $9.06M | $9.38M | $9.67M | $6.33M | $- |
| Deferred Revenue Non-Current | $3.62M | $3.87M | $4.52M | $5.33M | $9.11M | $10.12M | $12.01M | $12.63M | $12.92M | $11.83M | $12.70M | $13.58M | $14.21M | $12.21M | $8.54M | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $1 | $43.00K | $43.00K | $43.00K | $43.00K | $42.00K | $200.00K | $200.00K | $204.00K | $210.00K | $217.00K | $233.00K | $321.00K | $130.85M | $116.75M | $69.00K | $- |
| Total Non-Current Liabilities | $26.58M | $19.22M | $20.42M | $22.01M | $26.59M | $28.34M | $30.95M | $32.24M | $33.18M | $32.88M | $33.65M | $35.09M | $36.27M | $34.94M | $31.93M | $9.38M | $140.22M | $126.42M | $6.40M | $- |
| Other Liabilities | $- | $- | $- | $2 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $42.43M | $37.30M | $38.32M | $38.73M | $47.04M | $47.10M | $48.56M | $48.49M | $56.30M | $57.06M | $52.27M | $54.40M | $57.60M | $58.64M | $51.18M | $21.39M | $151.49M | $136.32M | $14.35M | $- |
| Preferred Stock | $- | $- | $- | $- | $159.78M | $- | $- | $- | $- | $- | $260.24M | $282.79M | $- | $333.55M | $347.07M | $324.64M | $105.30M | $105.30M | $118.83M | $77.50M |
| Common Stock | $- | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Retained Earnings | $-427.40M | $-411.47M | $-396.29M | $-375.10M | $-364.29M | $-346.38M | $-330.12M | $-312.07M | $-295.09M | $-275.09M | $-253.33M | $-230.67M | $-206.99M | $-179.83M | $-156.44M | $-132.85M | $-108.40M | $-77.36M | $-67.36M | $- |
| Accumulated Other Comprehensive Income Loss | $97.00K | $- | $-44.00K | $-36.00K | $37.00K | $-174.00K | $-229.00K | $-235.00K | $-919.00K | $-1.71M | $-1.80M | $-1.40M | $-321.00K | $-38.00K | $-23.00K | $-64.00K | $- | $2.00K | $1.00K | $-45.85M |
| Other Total Stockholders Equity | $484.50M | $483.50M | $482.19M | $479.29M | $476.99M | $474.81M | $472.49M | $469.99M | $467.51M | $465.25M | $463.10M | $460.46M | $457.43M | $454.78M | $452.36M | $436.17M | $3.45M | $-102.52M | $2.32M | $- |
| Total Stockholders Equity | $57.20M | $72.03M | $85.86M | $104.16M | $112.74M | $128.26M | $142.13M | $157.69M | $171.51M | $188.45M | $207.97M | $228.39M | $250.12M | $274.91M | $295.90M | $303.25M | $-104.95M | $-74.59M | $53.79M | $31.66M |
| Total Equity | $57.20M | $72.03M | $85.86M | $104.16M | $112.74M | $128.26M | $142.13M | $157.69M | $171.51M | $188.45M | $207.97M | $228.39M | $250.12M | $274.91M | $295.90M | $303.25M | $-104.95M | $-74.59M | $53.79M | $31.66M |
| Total Liabilities and Stockholders Equity | $99.63M | $109.33M | $124.18M | $142.89M | $159.78M | $175.35M | $190.70M | $206.18M | $227.81M | $245.50M | $260.24M | $282.79M | $307.72M | $333.55M | $347.07M | $324.64M | $46.54M | $61.74M | $68.14M | $31.66M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $99.63M | $109.33M | $124.18M | $142.89M | $159.78M | $175.35M | $190.70M | $206.18M | $227.81M | $245.50M | $260.24M | $282.79M | $307.72M | $333.55M | $347.07M | $324.64M | $46.54M | $61.74M | $68.14M | $31.66M |
| Total Investments | $63.00M | $75.03M | $91.33M | $110.31M | $119.56M | $132.20M | $143.63M | $156.13M | $183.59M | $198.94M | $201.00M | $201.19M | $244.18M | $266.88M | $252.62M | $207.42M | $17.30M | $19.95M | $8.04M | $69.65M |
| Total Debt | $25.21M | $18.18M | $18.89M | $19.57M | $20.22M | $20.86M | $21.47M | $22.05M | $22.61M | $23.24M | $22.89M | $23.37M | $24.36M | $24.93M | $25.48M | $10.68M | $10.88M | $11.02M | $6.33M | $- |
| Net Debt | $18.00M | $8.81M | $12.69M | $15.30M | $9.41M | $11.70M | $8.02M | $7.22M | $13.37M | $12.62M | $276.00K | $-20.65M | $-3.03M | $1.28M | $-32.82M | $-84.80M | $5.33M | $-6.78M | $-38.98M | $34.83M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-63.12M | $-69.20M | $-88.10M | $-98.59M | $-60.73M |
| Depreciation and Amortization | $1.78M | $1.85M | $1.67M | $1.19M | $611.00K |
| Deferred Income Tax | $- | $- | $- | $2.76M | $34.00K |
| Stock Based Compensation | $7.41M | $9.22M | $9.58M | $8.50M | $1.42M |
| Change in Working Capital | $-8.44M | $-9.86M | $-3.06M | $20.51M | $-2.28M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-4.88M | $-3.41M | $2.77M | $6.68M | $2.88M |
| Other Working Capital | $-3.56M | $-6.45M | $-5.83M | $13.83M | $-5.17M |
| Other Non Cash Items | $1.08M | $-1.54M | $3.41M | $8.56M | $13.64M |
| Net Cash Provided by Operating Activities | $-61.29M | $-69.53M | $-76.50M | $-57.07M | $-47.31M |
| Investments in Property Plant and Equipment | $-41.00K | $-206.00K | $-1.95M | $-2.34M | $-3.26M |
| Acquisitions Net | $- | $- | $-59.81M | $229.86M | $17.33M |
| Purchases of Investments | $-88.86M | $-164.99M | $-180.70M | $-313.38M | $-33.23M |
| Sales Maturities of Investments | $146.32M | $236.23M | $240.52M | $83.51M | $15.90M |
| Other Investing Activities | $148.00K | $- | $59.81M | $-229.86M | $-17.33M |
| Net Cash Used for Investing Activities | $57.58M | $71.04M | $57.86M | $-232.20M | $-20.59M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $108.00K | $253.00K | $503.00K | $259.21M | $294.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $51.90M | $39.30M |
| Net Cash Used Provided by Financing Activities | $108.00K | $253.00K | $503.00K | $311.11M | $39.60M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-3.60M | $1.77M | $-18.14M | $21.84M | $-28.30M |
| Cash at End of Period | $8.97M | $12.57M | $10.81M | $28.95M | $7.11M |
| Cash at Beginning of Period | $12.57M | $10.81M | $28.95M | $7.11M | $35.41M |
| Operating Cash Flow | $-61.29M | $-69.53M | $-76.50M | $-57.07M | $-47.31M |
| Capital Expenditure | $-41.00K | $-206.00K | $-1.95M | $-2.34M | $-3.26M |
| Free Cash Flow | $-61.33M | $-69.73M | $-78.46M | $-59.40M | $-50.57M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-15.94M | $-15.18M | $-21.20M | $-10.81M | $-17.90M | $-16.26M | $-18.06M | $-16.98M | $-20.00M | $-21.76M | $-22.66M | $-23.68M | $-27.16M | $-23.39M | $-23.59M | $-24.45M | $-31.04M | $-10.00M | $-11.06M | $-8.63M |
| Depreciation and Amortization | $426.00K | $440.00K | $457.00K | $458.00K | $497.00K | $462.00K | $458.00K | $467.00K | $462.00K | $439.00K | $408.00K | $357.00K | $361.00K | $304.00K | $256.00K | $272.00K | $221.00K | $179.00K | $110.00K | $101.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-3.06M | $-1.33M | $-1.11M | $- | $- | $- | $- | $- | $929.00K | $822.00K | $740.00K | $271.00K | $55.00K | $31.00K | $-19.00K | $-33.00K |
| Stock Based Compensation | $1.18M | $1.10M | $2.83M | $2.30M | $2.07M | $2.33M | $2.35M | $2.48M | $2.12M | $2.14M | $2.39M | $2.92M | $2.14M | $2.23M | $2.02M | $2.11M | $569.00K | $403.00K | $223.00K | $225.00K |
| Change in Working Capital | $-1.20M | $-578.00K | $1.77M | $-8.44M | $1.54M | $-2.69M | $518.00K | $-9.23M | $-774.00K | $5.08M | $-1.82M | $-5.55M | $5.39M | $555.00K | $15.94M | $-1.37M | $2.63M | $-1.21M | $-1.98M | $-1.72M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $-3.54M | $3.20M | $- | $- | $-6.61M | $8.25M | $- | $-3.09M | $-2.39M | $6.68M | $- | $- | $-88.00K | $2.88M | $- | $- | $- |
| Other Working Capital | $-1.20M | $-578.00K | $1.77M | $-8.44M | $1.54M | $-2.69M | $518.00K | $-2.62M | $-9.02M | $-1.21M | $1.27M | $-3.16M | $-1.29M | $555.00K | $15.94M | $-1.28M | $-248.00K | $-1.21M | $-1.98M | $-1.72M |
| Other Non Cash Items | $1.09M | $250.00K | $-3.00K | $2.96M | $2.60M | $744.00K | $731.00K | $-133.00K | $234.00K | $682.00K | $894.00K | $1.64M | $544.00K | $761.00K | $644.00K | $6.61M | $14.67M | $-1.91M | $459.00K | $426.00K |
| Net Cash Provided by Operating Activities | $-14.43M | $-13.97M | $-16.14M | $-16.75M | $-14.27M | $-16.75M | $-15.11M | $-23.40M | $-17.95M | $-13.45M | $-20.79M | $-24.31M | $-17.79M | $-18.73M | $-3.99M | $-16.56M | $-12.89M | $-12.52M | $-12.27M | $-9.64M |
| Investments in Property Plant and Equipment | $- | $-41.00K | $- | $- | $-6.00K | $-165.00K | $-32.00K | $-3.00K | $-184.00K | $-735.00K | $-429.00K | $-605.00K | $-562.00K | $-1.01M | $-703.00K | $-58.00K | $-898.00K | $-1.15M | $-840.00K | $-373.00K |
| Acquisitions Net | $- | $- | $- | $- | $55.43M | $-12.82M | $-13.61M | $-28.99M | $-16.62M | $- | $439.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-13.25M | $-20.32M | $-32.23M | $-23.06M | $-32.16M | $-36.30M | $-53.64M | $-42.88M | $-25.36M | $-47.91M | $-31.35M | $-76.08M | $-29.69M | $-35.92M | $-49.70M | $-198.07M | $- | $-19.99M | $- | $-13.23M |
| Sales Maturities of Investments | $25.48M | $37.35M | $50.23M | $33.26M | $47.98M | $49.13M | $67.25M | $71.88M | $41.98M | $50.10M | $30.91M | $117.53M | $51.28M | $20.82M | $3.80M | $7.61M | $2.60M | $8.05M | $5.25M | $- |
| Other Investing Activities | $- | $148.00K | $- | $10.20M | $-1 | $12.82M | $13.61M | $28.99M | $16.62M | $2.19M | $-439.00K | $41.45M | $21.59M | $-15.10M | $-45.90M | $-190.46M | $2.60M | $-11.94M | $5.25M | $-13.23M |
| Net Cash Used for Investing Activities | $12.23M | $17.14M | $18.00M | $10.20M | $15.81M | $12.66M | $13.58M | $28.99M | $16.43M | $1.45M | $-868.00K | $40.84M | $21.03M | $-16.11M | $-46.60M | $-190.52M | $1.70M | $-13.10M | $4.41M | $-13.61M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $29.00K | $- | $79.00K | $- | $106.00K | $- | $147.00K | $- | $144.00K | $- | $252.00K | $107.00K | $495.00K | $185.00K | $13.41M | $245.12M | $78.00K | $177.00K | $5.00K | $34.00K |
| Common Stock Repurchased | $- | $-79.00K | $79.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $51.90M | $-1.14M | $-1.20M | $83.10M | $- |
| Net Cash Used Provided by Financing Activities | $29.00K | $- | $79.00K | $- | $106.00K | $- | $147.00K | $- | $144.00K | $- | $252.00K | $107.00K | $495.00K | $185.00K | $13.41M | $297.02M | $-1.06M | $-923.00K | $41.55M | $34.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $14.36M | $- | $-14.36M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-2.17M | $3.17M | $1.94M | $-6.55M | $1.65M | $-4.09M | $-1.39M | $5.59M | $-1.37M | $-12.00M | $-21.40M | $16.64M | $3.73M | $-34.65M | $-37.18M | $89.94M | $-12.25M | $-26.53M | $33.69M | $-23.21M |
| Cash at End of Period | $8.97M | $11.14M | $6.20M | $4.26M | $10.81M | $10.93M | $15.02M | $16.40M | $10.81M | $12.18M | $24.18M | $45.59M | $28.95M | $25.21M | $59.87M | $97.05M | $7.11M | $19.36M | $45.89M | $12.20M |
| Cash at Beginning of Period | $11.14M | $7.97M | $4.26M | $10.81M | $9.16M | $15.02M | $16.40M | $10.81M | $12.18M | $24.18M | $45.59M | $28.95M | $25.21M | $59.87M | $97.05M | $7.11M | $19.36M | $45.89M | $12.20M | $35.41M |
| Operating Cash Flow | $-14.43M | $-13.97M | $-16.14M | $-16.75M | $-14.27M | $-16.75M | $-15.11M | $-23.40M | $-17.95M | $-13.45M | $-20.79M | $-24.31M | $-17.79M | $-18.73M | $-3.99M | $-16.56M | $-12.89M | $-12.52M | $-12.27M | $-9.64M |
| Capital Expenditure | $- | $-41.00K | $- | $- | $-6.00K | $-165.00K | $-32.00K | $-3.00K | $-184.00K | $-735.00K | $-429.00K | $-605.00K | $-562.00K | $-1.01M | $-703.00K | $-58.00K | $-898.00K | $-1.15M | $-840.00K | $-373.00K |
| Free Cash Flow | $-14.43M | $-14.01M | $-16.14M | $-16.75M | $-14.27M | $-16.91M | $-15.14M | $-23.40M | $-18.14M | $-14.19M | $-21.22M | $-24.92M | $-18.36M | $-19.74M | $-4.69M | $-16.62M | $-13.79M | $-13.67M | $-13.11M | $-10.01M |
Bolt Biotherapeutics Dividends
Explore Bolt Biotherapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
-1494.85x
Bolt Biotherapeutics Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.09 | $0.09 | August 29, 2014 | October 02, 2014 | August 13, 2014 | |
| $0.09 | $0.09 | June 10, 2014 | July 09, 2014 | April 24, 2014 | |
| $0.09 | $0.09 | March 03, 2014 | April 02, 2014 | January 22, 2014 | |
| $0.09 | $0.09 | December 30, 2013 | January 15, 2014 | November 27, 2013 | |
| $0.09 | $0.09 | September 03, 2013 | October 03, 2013 | August 14, 2013 | |
| $0.07 | $0.07 | June 03, 2013 | July 05, 2013 | April 24, 2013 | |
| $0.07 | $0.07 | March 05, 2013 | April 04, 2013 | January 25, 2013 | |
| $0.07 | $0.07 | November 30, 2012 | December 18, 2012 | November 21, 2012 | |
| $0.07 | $0.07 | September 04, 2012 | October 04, 2012 | August 22, 2012 | |
| $0.05 | $0.05 | June 04, 2012 | July 06, 2012 | April 26, 2012 | |
| $0.05 | $0.05 | March 06, 2012 | April 05, 2012 | January 25, 2012 |
Bolt Biotherapeutics News
Read the latest news about Bolt Biotherapeutics, including recent articles, headlines, and updates.
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended December 31, 2024, and provided a business update.
Bolt Biotherapeutics to Participate in Upcoming March Conferences
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 45th Annual Health Care Conference Company presentation on Tuesday, March 4, 2025 at 3:10 p.m.
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The collaborators are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types. Under the existing Joint Development and License Agreement, Toray supplies its proprietary antibodies targeting Caprin-1, such as the antibody TRK-950, and Bolt contributes proprietary linker-payloads from its Boltbody™ ISAC platform technology. Bolt plans to co-develop and jointly commercialize the resulting ISAC product candidate with Toray.
CSE Bulletin: Stock Split - Bolt Metals Corp. (BOLT)
Toronto, Ontario--(Newsfile Corp. - Le 11 novembre/November 2024) - Bolt Metals Corp. has announced a two (2) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive one (1) additional share for each share held on such date.
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston, Texas from November 6-10, 2024.
Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
Bolt Biotherapeutics Announces Changes to its Board of Directors
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair.
Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT) and certain officers.
The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
BOLT FINAL DEADLINE: Bronstein, Gewirtz and Grossman, LLC Reminds Bolt Biotherapeutics, Inc. Shareholders of Final Hours to Lead Class Action!
NEW YORK CITY, NY / ACCESSWIRE / September 3, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , Sept. 3, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024. Bolt describes itself as a “clinical-stage biopharmaceutical company, [that] engages in the development of immunotherapies for the treatment of cancer.” For more information, submit a form, email attorney Phillip Kim, or give us a ca.
Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
IMMINENT BOLT DEADLINE to Actively Participate in the Class Action Lawsuit for Bolt Biotherapeutics, Inc.: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Last Few Hours!
NEW YORK CITY, NY / ACCESSWIRE / September 2, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BOLT
NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv-03985, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bolt securities between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
A Securities Fraud Lawsuit Has Been Filed On Behalf Of Investors In Bolt Biotherapeutics Inc And The Schall Law Firm Wants Affected Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / September 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bolt To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Bolt between February 5, 2021 and May 14, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 31, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT) and reminds investors of the September 3, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit
NEW YORK , Aug. 30, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), of the important September 3, 2024 lead plaintiff deadline. So What: If you purchased Bolt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ: BOLT) and certain of its officers.
The Schall Law Firm Is Looking For Investors With Losses In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Case
LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / August 30, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for BOLT.